JIČÍNSKÁ, Hana, P. VLASIN, M. JICINSKY, I. GROCHOVA, V. TOMEK, J. VOLAUFOVA, J. SKOVRANEK a J. MAREK. Does First-Trimester Screening Modify the Natural History of Congenital Heart Disease? Analysis of Outcome of Regional Cardiac Screening at 2 Different Time Periods. Circulation. Philadelphia: Lippincott Williams Wilkins, roč. 135, č. 11, s. 1045-1055. ISSN 0009-7322. doi:10.1161/CIRCULATIONAHA.115.020864. 2017.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Does First-Trimester Screening Modify the Natural History of Congenital Heart Disease? Analysis of Outcome of Regional Cardiac Screening at 2 Different Time Periods
Autoři JIČÍNSKÁ, Hana (203 Česká republika, garant, domácí), P. VLASIN (203 Česká republika), M. JICINSKY (203 Česká republika), I. GROCHOVA (203 Česká republika), V. TOMEK (203 Česká republika), J. VOLAUFOVA (840 Spojené státy), J. SKOVRANEK (203 Česká republika) a J. MAREK (203 Česká republika).
Vydání Circulation, Philadelphia, Lippincott Williams Wilkins, 2017, 0009-7322.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 18.881
Kód RIV RIV/00216224:14110/17:00098539
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1161/CIRCULATIONAHA.115.020864
UT WoS 000396215400012
Klíčová slova anglicky congenital heart defects; echocardiography; epidemiology; first-trimester screening; prenatal cardiology
Štítky EL OK
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Soňa Böhmová, učo 232884. Změněno: 21. 3. 2018 16:14.
Anotace
BACKGROUND: The study analyzed the impact of first-trimester screening on the spectrum of congenital heart defects (CHDs) later in pregnancy and on the outcome of fetuses and children born alive with a CHD. METHODS: The spectrum of CHDs, associated comorbidities, and outcome of fetuses, either diagnosed with a CHD in the first trimester (Group I, 127 fetuses) or only in the second-trimester screening (Group II, 344 fetuses), were analyzed retrospectively between 2007 and 2013. Second-trimester fetuses diagnosed with a CHD between 2007 and 2013 were also compared with Group III (532 fetuses diagnosed with a CHD in the second trimester from 1996 to 2001, the period before first-trimester screening was introduced). RESULTS: The spectrum of CHDs diagnosed in the first and second trimesters in the same time period differed significantly, with a greater number of comorbidities (P< 0.0001), CHDs with univentricular outcome (P< 0.0001), intrauterine deaths (P= 0.01), and terminations of pregnancy (P< 0.0001) in Group I compared with Group II. In Group III, significantly more cases of CHDs with univentricular outcome (P< 0.0001), intrauterine demise (P= 0.036), and early termination (P< 0.0001) were identified compared with fetuses diagnosed with CHDs in the second trimester between 2007 and 2013. The spectrum of CHDs seen in the second-trimester groups differed after first-trimester screening was implemented. CONCLUSIONS: First-trimester screening had a significant impact on the spectrum of CHDs and the outcomes of pregnancies with CHDs diagnosed in the second trimester. Early detection of severe forms of CHDs and significant comorbidities resulted in an increased pregnancy termination rate in the first trimester.
VytisknoutZobrazeno: 28. 3. 2024 19:51